[1] Tsai, K. C., Huang, Y. C., Liaw, C. C., Tsai, C. I., Chiou, C. T., Lin, C. J., … & Su, Y. C. (2021). A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomedicine & Pharmacotherapy, 133, 111037.
[3] Jan, J. T., Cheng, T. J. R., Juang, Y. P., Ma, H. H., Wu, Y. T., Yang, W. B., … & Wong, C. H. (2021). Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences, 118(5).
其中的描述「Overall, in the in vivo assay, mefloquine and nelfinavir were identified as potential drug-repurposing agents and extracts of M. haplocalyx, P. frutescens, and RF3 showed potential as anti–SARS-CoV-2 herbal candidates.」 代表研究者認可其具有做為臨床試驗藥物的潛力。
Tsai, K. C., Huang, Y. C., Liaw, C. C., Tsai, C. I., Chiou, C. T., Lin, C. J., … & Su, Y. C. (2021). A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomedicine & Pharmacotherapy, 133, 111037.